In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), ...

Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing ...

Dianthus Therapeutics, Inc. is headquartered in New York City. The company is focused on developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Dianthus Therapeutics has a 52 week low of $18.34 and a 52 week high of $33.77. The stock has a market cap of $659.78 million, a P/E ratio of -8.92 and a beta of 1.72.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview ...

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

R Squared Ltd bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC.The institutional ...

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

Live webcasts of the Company’s presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage ...